NIH Names Dr Philip E. Bourne First Associate Director for Data Science

National Institutes of Health Director Francis S. Collins, MD, PhD, has announced the selection of Philip E. Bourne, PhD, as the first permanent Associate Director for Data Science (ADDS). Dr Bourne is expected to join the NIH in early 2014.
“Phil will lead an NIH-wide priority initiative to take better advantage of the exponential growth of biomedical research datasets, which is an area of critical importance to biomedical research. The era of ‘Big Data’ has arrived, and it is vital that the NIH play a major role in co-ordinating access to and analysis of many different data types that make up this revolution in biological information,” said Collins.
Dr Bourne comes to the NIH from the University of California San Diego, where he is the Associate Vice Chancellor for Innovation and Industry Alliances of the Office of Research Affairs and a Professor in the Department of Pharmacology and the Skaggs School of Pharmacy and Pharmaceutical Sciences. He also is the Associate Director of the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank. Dr Bourne was trained as a physical chemist and obtained his PhD from The Flinders University in South Australia.
Dr Bourne’s professional interests focus on relevant biological and educational outcomes derived from computation and scholarly communication. This work involves the use of algorithms, text mining, machine learning, metalanguages, biological databases, and visualisation applied to problems in systems pharmacology, evolution, cell signaling, apoptosis, immunology and scientific dissemination. He has published more than 300 papers and five books. One area to which he is extremely committed is to furthering the free dissemination of science through new models of publishing and better integration and subsequent dissemination of data and results.
Collins added: “I also must recognise and thank Dr Eric Green, who served as the Acting ADDS since I announced the search to fill this new position. His willingness to take on this challenging role in its inception, and to get the ball rolling on the enormous tasks that accompany this high-priority initiative, is sincerely appreciated. Eric is certain to remain a tremendous source of knowledge and support as Phil continues the NIH’s effort to manage ‘Big Data’.”
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News 3 ways ChatGPT will impact pharma marketing teams
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers? -
News Eli Lilly, Novo Nordisk, and Sanofi cut insulin prices by up to 78%
Insulin prices have dropped in a stark play by the three biggest makers of the product, after calls from the top of the US government. -
News Open letter challenges EU Commission on medicine supply chain
In an open letter to the European Commission, Medicines for Europe calls for a new medicine security contract with their goal to improve access to medicine and ensure a secure supply chain to Europe.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance